

Guilin Tang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6932653/publications.pdf>

Version: 2024-02-01

100
papers

2,292
citations

201674

27
h-index

254184

43
g-index

101
all docs

101
docs citations

101
times ranked

3130
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2022, 63, 710-721.	1.3	8
2	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 202-212.	1.6	34
3	Ibrutinib+rituximab followed by R-HCVAD as frontline treatment for young patients (≥65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 406-415.	10.7	22
4	3q21CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant. <i>Annals of Hematology</i> , 2022, 101, 847-854.	1.8	2
5	Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. <i>Leukemia</i> , 2022, 36, 1343-1350.	7.2	23
6	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894.	4.1	4
7	Hypomethylating agent and venetoclax with FLT3 inhibitor +triple therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	6.2	33
8	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1142-1149.	2.4	7
9	TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. <i>American Journal of Hematology</i> , 2022, 97, 1005-1012.	4.1	6
10	MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome. <i>Cancers</i> , 2022, 14, 2433.	3.7	7
11	Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. <i>Pathology</i> , 2022, , .	0.6	0
12	MET Amplification (MET/CEP7 Ratio ≈ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naïve Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e512-e518.	2.6	10
13	Triple hit SOX11, MME, TP53 mutated high-grade pleomorphic mantle cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 165-166.	4.1	2
14	Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome. <i>Experimental and Molecular Pathology</i> , 2021, 118, 104572.	2.1	3
15	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	5.0	50
16	Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement. <i>British Journal of Haematology</i> , 2021, 192, e17-e21.	2.5	2
17	MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. <i>Human Pathology</i> , 2021, 108, 22-31.	2.0	6
18	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. <i>American Journal of Hematology</i> , 2021, 96, E137-E140.	4.1	6

#	ARTICLE	IF	CITATIONS
19	Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy. <i>The Journal of Breast Health</i> , 2021, 17, 128-136.	1.0	7
20	Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021, 34, 1673-1685.	5.5	21
21	Outcomes of acute lymphoblastic leukemia with <i>KMT2A</i> (<i>MLL</i>) rearrangement: the MD Anderson experience. <i>Blood Advances</i> , 2021, 5, 5415-5419.	5.2	24
22	Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2021, 108, 106616.	0.8	2
23	Blast phase of chronic myeloid leukemia presenting as early T-cell precursor lymphoblastic leukemia. <i>EJHaem</i> , 2021, 2, 895.	1.0	0
24	Clonal cytogenetic abnormalities in donor-derived cells after sex mismatched allogeneic stem cell transplantation. <i>Cancer Genetics</i> , 2021, 258-259, 120-130.	0.4	0
25	CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. <i>Cancers</i> , 2021, 13, 5354.	3.7	3
26	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 665-671.	2.0	21
27	Anaplastic multiple myeloma resembling dysplastic megakaryocytes. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 568-569.	0.5	3
28	Acute myeloid leukemia with a novel CPSF6- <i>RARG</i> variant is sensitive to homoharringtonine and cytarabine chemotherapy. <i>American Journal of Hematology</i> , 2020, 95, E48-E51.	4.1	19
29	Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. <i>Blood Advances</i> , 2020, 4, 4834-4837.	5.2	11
30	Acute promyelocytic leukemia (APL) with an <i>IRF2BP2-RARA</i> fusion transcript: an aggressive APL variant. <i>Leukemia and Lymphoma</i> , 2020, 61, 3018-3020.	1.3	6
31	Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes. <i>Cancers</i> , 2020, 12, 1903.	3.7	0
32	Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2831-2838.	1.3	11
33	LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2020, 99, 2343-2349.	1.8	3
34	"Double hit" anaplastic large cell lymphoma with concurrent <i>ALK</i> and <i>MYC</i> rearrangements. <i>American Journal of Hematology</i> , 2020, 95, 1625-1627.	4.1	1
35	Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. <i>Leukemia Research</i> , 2020, 99, 106460.	0.8	14
36	iAMP21 in acute myeloid leukemia is associated with complex karyotype, TP53 mutation and dismal outcome. <i>Modern Pathology</i> , 2020, 33, 1389-1397.	5.5	8

#	ARTICLE	IF	CITATIONS
37	Systematic use of fluorescence <i>in situ</i> hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms. <i>Histopathology</i> , 2020, 76, 1042-1054.	2.9	13
38	MYC rearrangement and MYC/BCL2 double expression but not cell of origin predict prognosis in R-CHOP-treated diffuse large cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 336-343.	2.2	15
39	<i>Hematopathology</i> , 2020, , 1729-2141.		0
40	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) –outcomes and mutation profile from venetoclax resistant MCL patients. <i>American Journal of Hematology</i> , 2020, 95, 623-629.	4.1	54
41	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , 2020, 4, 1038-1050.	5.2	43
42	t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?. <i>Annals of Hematology</i> , 2020, 99, 487-500.	1.8	6
43	Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E256-E259.	4.1	4
44	Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies. <i>Data in Brief</i> , 2019, 24, 104025.	1.0	3
45	Is hyperdiploidy a favorable cytogenetics in adults with B-lymphoblastic leukemia?. <i>Cancer Medicine</i> , 2019, 8, 4093-4099.	2.8	10
46	Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes. <i>Experimental and Molecular Pathology</i> , 2019, 108, 131-136.	2.1	1
47	Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2019, 60, 2993-3001.	1.3	8
48	Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy. <i>Case Reports in Pathology</i> , 2019, 2019, 1-10.	0.3	0
49	Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults. <i>Annals of Hematology</i> , 2019, 98, 1149-1157.	1.8	23
50	Merkel cell carcinoma mimicking transformed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2256-2257.	0.5	1
51	SOX11-negative Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 710-716.	3.7	22
52	Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 305-311.	3.5	56
53	t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 343-351.	2.8	16
54	Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. <i>Modern Pathology</i> , 2019, 32, 490-498.	5.5	50

#	ARTICLE	IF	CITATIONS
55	How I investigate Clonal cytogenetic abnormalities of undetermined significance. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 385-391.	1.3	16
56	8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. <i>Leukemia Research</i> , 2018, 66, 73-78.	0.8	29
57	Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. <i>Modern Pathology</i> , 2018, 31, 1141-1154.	5.5	23
58	Bone marrow findings in blast phase of polycythemia vera. <i>Annals of Hematology</i> , 2018, 97, 425-434.	1.8	13
59	Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors. <i>Cancer Genetics</i> , 2018, 228-229, 41-46.	0.4	10
60	MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. <i>Modern Pathology</i> , 2018, 31, 1470-1478.	5.5	50
61	Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1. <i>Annals of Hematology</i> , 2018, 97, 1775-1783.	1.8	11
62	CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. <i>Oncotarget</i> , 2018, 9, 11441-11450.	1.8	27
63	Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus, but not <i>MLL</i> gene. <i>Journal of Clinical Pathology</i> , 2017, 70, 244-249.	2.0	7
64	Myeloid neoplasms with concurrent <i>BCR-ABL1</i> and <i>CBFB</i> rearrangements: A series of 10 cases of a clinically aggressive neoplasm. <i>American Journal of Hematology</i> , 2017, 92, 520-528.	4.1	23
65	Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 441-447.	4.1	26
66	Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. <i>Haematologica</i> , 2017, 102, 1511-1518.	3.5	35
67	Clinical significance of isolated del(7p) in myeloid neoplasms. <i>Leukemia Research</i> , 2017, 55, 18-22.	0.8	6
68	Tetraploidy/near-tetraploidy acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 53, 20-27.	0.8	12
69	Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. <i>Blood</i> , 2017, 130, 2084-2091.	1.4	65
70	Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2017, 30, 1688-1697.	5.5	46
71	An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma. <i>Case Reports in Hematology</i> , 2017, 2017, 1-4.	0.4	11
72	Acquired 11q23/ rearrangement of unknown clinical significance. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 9048-9051.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. <i>Modern Pathology</i> , 2016, 29, 727-734.	5.5	8
74	Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. <i>Blood</i> , 2016, 127, 2742-2750.	1.4	145
75	Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists. <i>Molecular Cytogenetics</i> , 2016, 9, 62.	0.9	9
76	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. <i>American Journal of Surgical Pathology</i> , 2016, 40, 253-261.	3.7	51
77	Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype. <i>Cancer Genetics</i> , 2016, 209, 313-320.	0.4	37
78	Simultaneous deletion of 3â€²ETV6 and 5â€²EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. <i>Molecular Cytogenetics</i> , 2016, 9, 23.	0.9	21
79	Clinical significance of acquired loss of the X chromosome in bone marrow. <i>Leukemia Research</i> , 2016, 47, 109-113.	0.8	9
80	Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult Bâ€²cell acute lymphoblastic leukemia (Bâ€²ALL) with <i>TET2</i> and <i>TP53</i> mutations. <i>American Journal of Hematology</i> , 2016, 91, 354-355.	4.1	3
81	The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia. <i>Modern Pathology</i> , 2016, 29, 444-451.	5.5	18
82	Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. <i>Journal of Hematology and Oncology</i> , 2015, 8, 65.	17.0	102
83	Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 882-887.	4.1	14
84	TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. <i>Journal of Hematology and Oncology</i> , 2015, 8, 45.	17.0	101
85	Isolated +15 in bone marrow: Disease-associated or a benign finding?. <i>Leukemia Research</i> , 2015, 39, 72-76.	0.8	12
86	Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. <i>Leukemia Research</i> , 2015, 39, 348-354.	0.8	115
87	Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant. <i>American Journal of Clinical Pathology</i> , 2015, 144, 78-86.	0.7	13
88	Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 32.	17.0	30
89	The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 504-510.	4.1	33
90	Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. <i>Modern Pathology</i> , 2015, 28, 1014-1022.	5.5	20

#	ARTICLE	IF	CITATIONS
91	Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. <i>European Journal of Haematology</i> , 2015, 95, 168-176.	2.2	30
92	MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation. <i>Human Pathology</i> , 2015, 46, 65-73.	2.0	32
93	Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. <i>American Journal of Hematology</i> , 2014, 89, 813-818.	4.1	66
94	Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. <i>Leukemia Research</i> , 2014, 38, 896-900.	0.8	8
95	Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chromosomal abnormalities in <i>SM</i> and <i>AHNMD</i> components. <i>American Journal of Hematology</i> , 2013, 88, 219-224.	4.1	76
96	Chronic lymphocytic leukemia with t(14;18)(q32;q21). <i>Human Pathology</i> , 2013, 44, 598-605.	2.0	22
97	Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Modern Pathology</i> , 2012, 25, 237-245.	5.5	67
98	Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. <i>Leukemia Research</i> , 2012, 36, 974-981.	0.8	30
99	Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes. <i>Cancer</i> , 2008, 113, 3331-3340.	4.1	102
100	Myeloid neoplasms with 8q24/ <i>MYC</i> rearrangement are frequently associated with myelodysplasia, complex karyotype, <i>TP53</i> alterations, and inferior survival. <i>British Journal of Haematology</i> , 0, , .	2.5	0